Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Cognitive Remediation Therapy Within a Secure Forensic Setting

24 juillet 2017 mis à jour par: Ken O'Reilly, Central Mental Hospital

Randomised Controlled Trial to Evaluate the Efficacy of Cognitive Remediation Within a Secure Forensic Setting for Schizophrenia Spectrum Patients

This clinical trial tests the feasibility, effectiveness and patient satisfaction with cognitive remediation therapy for patients diagnosed with schizophrenia or schizoaffective disorder within a forensic hospital. It is hypothesised that patients receiving cognitive remediation therapy will have an improvement in cognitive performance, real world functioning, symptoms, violence risk and benefit more from additional psychosocial treatment programmes over time relative to patients receiving treatment as usual. Furthermore it is hypothesised that it will be feasible to carry out such a study and that patients will report high rates of satisfaction with cognitive remediation therapy. Finally it is hypothesised that differences on the effectiveness measures will be maintained at 6 month follow up after the end of treatment.

Aperçu de l'étude

Description détaillée

This is a single centre randomised clinical trial to evaluate the feasibility, effectiveness and patient satisfaction with cognitive remediation therapy within a secure forensic setting for patients diagnosed with schizophrenia or schizoaffective disorder.

The feasibility of the intervention will be assessed using key indicators such as rate of enrolment, retention of patients in the trial, blinding effectiveness, and completion rate of the primary outcome measure. The effectiveness of the intervention will be assessed using the MATRICS consensus cognitive battery, symptoms (PANSS and CAINS) and real world functioning (SOFAS: Social and occupational functioning assessment scale). The effect of cognitive remediation on violence risk (HCR-20), programme completion and recovery (Dundrum 3 & 4) will also be examined, where programme completion is a measure of attainments from participating in additional psychosocial interventions and recovery is a measure of stability of mental state.

Patient satisfaction with cognitive remediation therapy will be assessed using a consumer constructed interview developed by Rose et al (2008) and administered by a social worker not involved in the delivery of cognitive remediation.

The trial will take place at the Republic of Ireland's Central Mental Hospital (CMH). The CMH is the only secure forensic psychiatric hospital for the Republic of Ireland, a population of 4.6 million. CMH provides specialised care for adults who have a mental disorder and are at risk of harming themselves or others.

After a baseline assessment to ensure eligibility and to obtain consent, an estimated 60 patients will be randomised to receive fourteen weeks of cognitive remediation versus treatment as usual. Patients who receive treatment as usual will be offered cognitive remediation upon completion of the study. Patients allocated to cognitive remediation will receive three individual sessions of cognitive remediation a week and one group session, fifty-six sessions in total The focus of the group session is to normalise cognitive difficulties that patients may be experiencing, to receive support and to help generalise gains. The primary outcome measure the MATRICS composite score and secondary outcome measures to assess real world functioning, symptoms, violence risk, programme completion and recovery will be administered at baseline, the end of treatment and at six month follow up. Secondary measures will also include feasibility outcomes and patient satisfaction with cognitive remediation therapy. All evaluators of the effectiveness measures will be blind to participant treatment condition at the time of assessment.

The cognitive remediation therapy is a principle driven intervention consisting of nine treatment principles: Principle 1 refers to relationship building, Principle 2 refers to collaborative goal setting, Principle 3 involves the session structure, Principle 4 concerns the content of the sessions, Principle 5, concerns the pacing of sessions, Principle 6 involves scaffolding and errorless learning, Principle 7 refers to meta-cognitive strategies, Principle 8 involves generalisation of gains, finally Principle 9 refers to managing ambivalence. The actual therapy will involve the use of a combination on pen, paper and computerised materials to stimulate patient's cognitive capacity and to provide them with the opportunity to apply meta-cognitive strategies.

The investigators hypothesise that it is feasible to carry out a randomised controlled trial within a single centre forensic setting and that patients will report high rates of satisfaction with cognitive remediation. It is also hypothesised that patients receiving cognitive remediation therapy will have an improvement in cognitive performance (the primary outcome measure), real world functioning, symptoms and violence risk over time relative to patients receiving treatment as usual; specifically that there will be a treatment by time interaction. Furthermore it is hypothesised that these differences will be maintained at six month follow up after the end of treatment.

In addition it is hypothesised that patients receiving cognitive remediation will show an improvement over time on the Dundrum programme completion and recovery scales compared to those receiving treatment as usual.

While meta-analytic reviews have demonstrated that cognitive remediation therapy has a beneficial effect on the cognitive deficits experienced by patients with schizophrenia (Wykes et al 2011), to the best of our knowledge there has been no study with forensic mental health patients. The current study will help answer whether it is feasible to deliver cognitive remediation within a forensic mental health setting and whether it is acceptable to patients. The study aims to contribute to the evidence base for psychological interventions within a forensic setting and to answer the question as to whether cognitive remediation has a beneficial effect and if it does whether this effect is maintained over time.

Type d'étude

Interventionnel

Inscription (Réel)

65

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

      • Dublin, Irlande, D 14
        • Central Mental Hospital

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans à 65 ans (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • A Structured Clinical Interview for Diagnostic and Statistical Manual IV (SCID) diagnosis of schizophrenia or schizoaffective disorder.

Exclusion Criteria:

  • Acutely psychotic, or judged too dangerous to participate in treatment, or being over 65 years of age.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Seul

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Cognitive Remediation Therapy
Principle driven cognitive remediation therapy, cognitive rehabilitation, cognitive training, cognitive enhancement.
Fifty-six sessions of principle driven cognitive remediation therapy. Three individual sessions and one group session each week for approximately fourteen weeks.
Autres noms:
  • Entraînement cognitif
  • Amélioration cognitive
  • Rééducation cognitive
Comparateur actif: Treatment as Usual
Usual care.
Keep getting usual care.
Autres noms:
  • Soins standards

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
The MATRICS Consensus Cognitive Battery (MCCB)
Délai: Group by time interaction: changes from baseline, to end of treatment (average 5 months)
Consensus neuropsychological assessment battery for cognitive deficits in schizophrenia
Group by time interaction: changes from baseline, to end of treatment (average 5 months)

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Social and Occupational Functioning Assessment Scale (SOFAS)
Délai: Group by time interaction: changes from baseline, to end of treatment (average 5 months)
100 item rating scale for measuring real world functioning independent of symptoms
Group by time interaction: changes from baseline, to end of treatment (average 5 months)
Positive and Negative Syndrome Scale (negative and disorganized factors)
Délai: Group by time interaction: changes from baseline, to end of treatment (average 5 months)
Rating scale for assessing psychiatric symptoms associated with schizophrenia
Group by time interaction: changes from baseline, to end of treatment (average 5 months)
Clinical Assessment Interview for Negative Symptoms (CAINS)
Délai: Group by time interaction: changes from baseline, to end of treatment (average 5 months)
Rating scale for assessing the negative symptoms of schizophrenia
Group by time interaction: changes from baseline, to end of treatment (average 5 months)

Autres mesures de résultats

Mesure des résultats
Description de la mesure
Délai
Historical Clinical and Risk Management -20 (HCR-20)
Délai: Group by time interaction: changes from baseline, to 12 months
Rating scale for assessing violence risk
Group by time interaction: changes from baseline, to 12 months
Dundrum Toolkit: Programme Completion and Recovery Scales
Délai: Group by time interaction: changes from baseline to 12 months
Rating scale for assessing progress and recovery within a forensic mental health setting
Group by time interaction: changes from baseline to 12 months
Patient satisfaction.
Délai: Average 5 months.
Consumer developed interview exploring patient satisfaction with cognitive remediation.
Average 5 months.
Feasibility outcome: rate of enrolment.
Délai: 12 months.
Willingness of forensic mental health patients to participate in study.
12 months.
Feasibility outcome: rate of retention.
Délai: 12 months.
Number of patients who complete the intervention.
12 months.
Feasibility outcome: blinding.
Délai: 12 months.
Number of patients in which the blind is broken compared to number of patients in the study.
12 months.
Completion rate of primary outcome measures
Délai: 12 months.
Number of successfully completed primary outcome measures.
12 months.

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Directeur d'études: Professor Harry G Kennedy, M.D., Central Mental Hospital and Department of Psychiatry, Trinity College Dublin.
  • Directeur d'études: Professor Gary Donohoe, Ph.D., Department of Psychiatry, Trinity College Dublin.
  • Chercheur principal: Dr. Ken W O'Reilly, D.Psych.Sc., Central Mental Hospital and Department of Psychiatry, Trinity College Dublin.

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Publications générales

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude

1 août 2014

Achèvement primaire (Réel)

1 janvier 2017

Achèvement de l'étude (Réel)

1 janvier 2017

Dates d'inscription aux études

Première soumission

4 février 2015

Première soumission répondant aux critères de contrôle qualité

10 février 2015

Première publication (Estimation)

11 février 2015

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

25 juillet 2017

Dernière mise à jour soumise répondant aux critères de contrôle qualité

24 juillet 2017

Dernière vérification

1 juillet 2017

Plus d'information

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner